IP-2: intervening peptide 2
The American Diabetes Association now recommends GLP-1 RAs for patients with established ASCVD regardless of their A1C and regardless of if the patient is taking metformin, the historically first line medication for T2DM [38]
If you found this article helpful, dont forget to like , share , and Follow to stay up to date on our latest health tips, pharmacy updates, and wellness advice
By contrast, lower doses like 4 mg still produced meaningful loss, often in the low double-digit percentage range, though not to the same magnitude
You're already on tirzepatide and it's working, so should you switch to retatrutide
The variables most physicians miss full thyroid, hormones, ferritin, inflammation often reveal the actual bottleneck